Communiqués Vivos Inc.

Actions

RDGL

US92858K2042

Equipement et technologie médicale avancés

Marché Fermé - OTC Markets 21:59:52 09/10/2026			Varia. 5j.	Varia. 1 janv.
0,0486 ^USD	+5,83%		+6,11%	-29,46%

18/08	Vivos annonce les premières expéditions d'IsoPet depuis son laboratoire APEL à Richland, Washington	CI
12/08	Vivos Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

03/09	Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology	AQ
18/08	Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center	AQ
27/07	Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update	AQ
06/07	Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™	AQ
11/06	Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing	AQ
05/06	Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™	AQ
17/02	Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites	AQ
10/02	Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™	AQ
03/02	Vivos Inc Updates Human Therapy Progress in India	AQ
28/01	Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals	AQ
22/12	Vivos Inc Summarizes Progress in its Animal Therapy Division	AQ
22/12	Vivos Inc Summarzes Preogress in its Animal Therapy Division	AQ
06/11	Vivos Inc. Issues Shareholder Update Letter	AQ
29/10/25	Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics	AQ
27/10/25	Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®	AQ
29/09/25	Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India	AQ
08/09/25	Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy	AQ
03/09/25	Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization	AQ
14/08/25	Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA	AQ
14/07/25	Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic	AQ
15/05/25	Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™	AQ
23/04/25	Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025	AQ
15/04/25	Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™	AQ
04/02/25	Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans	AQ
26/12/24	Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide	AQ